...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Multiplex SNaPshot genotyping for detecting loss of heterozygosity in the mismatch-repair genes MLH1 and MSH2 in microsatellite-unstable tumors.
【24h】

Multiplex SNaPshot genotyping for detecting loss of heterozygosity in the mismatch-repair genes MLH1 and MSH2 in microsatellite-unstable tumors.

机译:多重SNaPshot基因分型用于检测微卫星不稳定肿瘤错配修复基因MLH1和MSH2中杂合性的丧失。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: In the workup of patients with suspected hereditary nonpolyposis colorectal cancer (HNPCC), detection of loss of heterozygosity (LOH) could help pinpoint the mismatch-repair (MMR) gene carrying the germline mutation, but analysis of microsatellite markers has proved unreliable for this purpose. We developed a simple, low-cost method based on single-nucleotide polymorphism (SNP) genotyping and capillary electrophoresis for the assessment of LOH at 2 MMR loci simultaneously. METHODS: We used the Applied Biosystems SNaPshot Multiplex Kit with meticulously selected primers to assess 14 common SNPs in MLH1 [mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)] and MSH2 [mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)] and optimized the protocol for DNA isolated from peripheral blood and fresh/frozen or archival microsatellite-unstable tumors from patients with confirmed (n = 42) or suspected (n = 25) HNPCC. The 42 tumors from patients with confirmed MLH1 or MSH2 germline mutations were used to validate the method's diagnostic accuracy against results obtained with DNA sequencing or multiplex ligation-dependent probe amplification. RESULTS: The SNaPshot assay provided better detection of certain SNPs than DNA sequencing. The MLH1 and MSH2 SNP marker sets were informative in 82% and 76% of the 67 cases analyzed, respectively. The new assay displayed 100% specificity for detecting LOH and predicted the location of the germline mutation in 40% of the cases (54% of those involving MLH1, 22% in MSH2). CONCLUSIONS: Our SNP-based method for detecting LOH in MLH1 and MSH2 is simple to perform with instruments available in most clinical genetics laboratories. It can be a valuable addition to protocols now used to guide mutational screening of patients with suspected HNPCC.
机译:背景:在怀疑患有遗传性非息肉性结直肠癌(HNPCC)的患者进行检查时,检测杂合性缺失(LOH)可能有助于查明携带种系突变的错配修复(MMR)基因,但是微卫星标记的分析已证明不可靠这个目的。我们开发了一种基于单核苷酸多态性(SNP)基因分型和毛细管电泳的简单,低成本方法,用于同时评估2个MMR基因座的LOH。方法:我们使用Applied Biosystems SNaPshot多重试剂盒,并精心选择引物,以评估MLH1 [mutL同源物1,结肠癌,非息肉病2型(大肠杆菌)]和MSH2 [mutS同源物2,结肠癌,非息肉病类型]中的14种常见SNP 1(E. coli)],并优化了从已确诊(n = 42)或疑似(n = 25)HNPCC患者的外周血和新鲜/冷冻或档案微卫星不稳定肿瘤中分离的DNA的方案。来自确诊为MLH1或MSH2种系突变的患者的42例肿瘤用于验证该方法对DNA测序或多重连接依赖性探针扩增结果的诊断准确性。结果:SNaPshot分析提供了比DNA测序更好地检测某些SNP的功能。 MLH1和MSH2 SNP标记物组分别在分析的67例病例中提供了82%和76%的信息。新的检测方法显示出100%的LOH特异性,并预测了40%的病例(54%的病例涉及MLH1,22%的MSH2)发生了种系突变。结论:我们基于SNP的MLH1和MSH2中LOH检测方法很容易使用大多数临床遗传学实验室中可用的仪器进行。它可以作为目前用于指导对疑似HNPCC患者进行突变筛查的方案的宝贵补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号